Stock ADIL ADIAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.45 USD -.--% Intraday chart for Adial Pharmaceuticals, Inc. +16.00% -22.04%
May. 14 Adial Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 22 Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder MT

Business Summary

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Number of employees: 6

Managers

Managers TitleAgeSince
Cary Claiborne CEO
 Chief Executive Officer 64 21-11-01
Joseph Truluck DFI
 Director of Finance/CFO 46 16-04-30
Julien Dimastromatteo CTO
 Chief Tech/Sci/R&D Officer - -
Tony Goodman COO
 Chief Operating Officer 60 17-06-30
John Rothwell Martin LAW
 General Counsel - -
Catherine Fratila AUD
 Comptroller/Controller/Auditor - -
Mark H. Peikin PRN
 Corporate Officer/Principal - 19-09-30
Alex Lugovoy PRN
 Corporate Officer/Principal - 19-04-10
Schuyler Vinzant PRN
 Corporate Officer/Principal - 19-12-31
Andrew E. Taubman PRN
 Corporate Officer/Principal - 20-01-31

Members of the board

Members of the board TitleAgeSince
Jack W. Reich LAW
 General Counsel - 20-05-18
Cary Claiborne CEO
 Chief Executive Officer 64 21-11-01
Tony Goodman COO
 Chief Operating Officer 60 17-06-30
J. Anderson BRD
 Director/Board Member 74 15-01-31
Robertson Gilliland BRD
 Director/Board Member 44 14-08-31
James Newman BRD
 Director/Board Member 81 14-08-31
Kevin Schuyler CHM
 Chairman 55 16-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,233,308 4,069,554 ( 96.13 %) 0 96.13 %

Shareholders

NameEquities%Valuation
Cary Claiborne
1.499 %
60,799 1.499 % 105 182 $
Renaissance Technologies LLC
1.260 %
51,100 1.260 % 88 403 $
Manchester Capital Management LLC
1.186 %
48,097 1.186 % 83 208 $
HRT Financial LLC
0.8821 %
35,767 0.8821 % 61 877 $
Bankole Johnson
0.5172 %
20,973 0.5172 % 36 283 $
Virtu Financial LLC
0.5048 %
20,469 0.5048 % 35 411 $
James Newman
0.3338 %
13,535 0.3338 % 23 416 $
Joseph Truluck
0.2615 %
10,605 0.2615 % 18 347 $
BlackRock Institutional Trust Co. NA
0.1884 %
7,639 0.1884 % 13 215 $
Kevin Schuyler
0.1625 %
6,589 0.1625 % 11 399 $

Company contact information

Adial Pharmaceuticals, Inc.

4870 Sadler Road Suite 300

23060, Glen Allen

+

http://www.adialpharma.com
address Adial Pharmaceuticals, Inc.(ADIL)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.45 USD
Average target price
7.5 USD
Spread / Average Target
+417.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ADIAL PHARMACEUTICALS, INC. Stock Adial Pharmaceuticals, Inc.
-22.04% 5.88M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ADIL Stock
  4. Company Adial Pharmaceuticals, Inc.